At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ICCM IceCure Medical Ltd.
Trading 11-05 09:50:31 EST
0.8101
-0.0399
-4.69%
High0.8607Low0.8100Vol48.60K
Open0.8600D1 Closing0.8500Amplitude5.96%
Mkt Cap44.96MTradable Cap23.23MTotal Shares55.50M
T/O40.20KT/O Rate0.17%Tradable Shares28.68M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
PR Newswire  ·  10-29
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
BRIEF-Icecure Receives Notice Of Allowance From U.S. Patent And Trademark Office For Its Next-Generation Cryoablation System
Reuters  ·  10-21
BRIEF-Icecure Receives Notice Of Allowance From U.S. Patent And Trademark Office For Its Next-Generation Cryoablation System
IceCure Medical Expands Patent Portfolio with New US Approval
TIPRANKS  ·  10-21
IceCure Medical Expands Patent Portfolio with New US Approval
IceCure Medical granted patent by USPTO for cryoablation system
TIPRANKS  ·  10-21
IceCure Medical granted patent by USPTO for cryoablation system
Icecure Receives Notice of Allowance From U.S. Patent and Trademark Office for Its Next-Generation Cryoablation System
THOMSON REUTERS  ·  10-21
Icecure Receives Notice of Allowance From U.S. Patent and Trademark Office for Its Next-Generation Cryoablation System
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
PR Newswire  ·  10-21
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
IceCure Medical files to sell ordinary shares and warrants, no amount given
TIPRANKS  ·  10-16
IceCure Medical files to sell ordinary shares and warrants, no amount given
Icecure Medical: A Strong Buy on Clinical Success and Upcoming Regulatory Catalysts
TIPRANKS  ·  10-14
Icecure Medical: A Strong Buy on Clinical Success and Upcoming Regulatory Catalysts
Alignment HealthCare Partners With Intermountain Health in Nevada
Zacks  ·  10-10
Alignment HealthCare Partners With Intermountain Health in Nevada
IceCure’s ProSense Excels in Global Cryoablation Studies
TIPRANKS  ·  10-07
IceCure’s ProSense Excels in Global Cryoablation Studies
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
PR Newswire  ·  10-07
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
Zacks  ·  10-03
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
Bet on 5 Top-Ranked Stocks With Rising P/E
Zacks  ·  10-02
Bet on 5 Top-Ranked Stocks With Rising P/E
IceCure Medical’s ProSense® Shows Promising Trial Results
TIPRANKS  ·  09-24
IceCure Medical’s ProSense® Shows Promising Trial Results
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
PR Newswire  ·  09-24
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
IceCure’s ProSense Shows High Success in Tumor Treatment
TIPRANKS  ·  09-16
IceCure’s ProSense Shows High Success in Tumor Treatment
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
PR Newswire  ·  09-16
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.
Dow Jones  ·  09-13
Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.
IceCure Medical’s ProSense Positioned for Market Success Following FDA Panel Meeting, Analyst Maintains Buy Rating
TIPRANKS  ·  09-13
IceCure Medical’s ProSense Positioned for Market Success Following FDA Panel Meeting, Analyst Maintains Buy Rating
FDA AdComm to discuss IceCure's ProSense on Nov. 7
seekingalpha  ·  09-12
FDA AdComm to discuss IceCure's ProSense on Nov. 7

Introduction

Company Name.
IceCure Medical Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Issue price:
--